Abstract: A sealing member includes a first sealing member and a second sealing member surrounding the first sealing member, wherein the first sealing member is configured to be disposed on an electrolyte injection port of a secondary battery, wherein the second sealing member is configured to be disposed on an outer surface of a case of the secondary battery external to the electrolyte injection port, and wherein no binder is applied to the first sealing member.

Abstract: A secondary battery includes a case comprising a body part having an opening formed therein and a cover part covering the opening. A stacked electrode assembly is accommodated in the case, the electrode assembly including a first electrode connected to a first substrate tab, a second electrode connected to a second substrate tab, a separator between the first and second electrode, a first lead tab having an end coupled to the first substrate tab, and a second lead tab having an end coupled to the second substrate tab. The electrode assembly includes a first adhesive member covering a coupling region between the first substrate tab and the first lead tab, a second adhesive member wrapping at least one of side surfaces of the electrode assembly and a portion of at least one of main surfaces of the electrode assembly, a third adhesive member wrapping a lower surface of the electrode assembly and a portion of at least one of the main surfaces, and a fourth adhesive member attached in an inclined region.

Abstract: The present invention provides a polypeptide for preventing or treating idiopathic pulmonary fibrosis, which is synthesized by linking 9 to 10 amino acids together and comprises an amino acid sequence consisting of arginine (R, Arg)-glycine (G, Gly)-aspartic acid (D, Asp)-valine (V, Val)-phenylalanine (F, Phe)-proline (P, Pro)-serine (S, Ser)-tyrosine (Y, Tyr)-threonine (T, Thr). Accordingly, the polypeptide for preventing or treating idiopathic pulmonary fibrosis according to the present invention may restore lung function to normal by fundamentally treating lung tissue that has undergone fibrosis due to idiopathic pulmonary fibrosis, and furthermore, may delay or prevent the onset of idiopathic pulmonary fibrosis.

Abstract: Provided is recombinant protein for ulcerative colitis treatment or prevention that is recombinant protein based on milk fat globule-EGF factor 8 (MFG-E8) protein, consisting of an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 3, to be administered to a target for treatment or prevention, thereby expecting treatment or prevention of ulcerative colitis. Further, provided is a composition for ulcerative colitis treatment or prevention containing recombinant protein based on milk fat globule-EGF factor 8 (MFG-E8) protein, consisting of an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 3, as an active ingredient.

Abstract: The present invention provides a polypeptide for preventing or treating idiopathic pulmonary fibrosis, which is synthesized by linking 9 to 10 amino acids together and comprises an amino acid sequence consisting of arginine (R, Arg)-glycine (G, Gly)-aspartic acid (D, Asp)-valine (V, Val)-phenylalanine (F, Phe)-proline (P, Pro)-serine (S, Ser)-tyrosine (Y, Tyr)-threonine (T, Thr). Accordingly, the polypeptide for preventing or treating idiopathic pulmonary fibrosis according to the present invention may restore lung function to normal by fundamentally treating lung tissue that has undergone fibrosis due to idiopathic pulmonary fibrosis, and furthermore, may delay or prevent the onset of idiopathic pulmonary fibrosis.